MULTIMODAL SPECTROSCOPIC EVALUATION OF CERVICAL CANCER

宫颈癌的多模态光谱评估

• 批准号: 6298487
• 负责人: Shabbir Bakir Bambot
• 金额: $ 12.96万
• 依托单位: GUIDED THERAPEUTICS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-08-01 至 2002-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298487
• 关键词: bioengineering /biomedical engineering; bioimaging /biomedical imaging; biomedical equipment development; cervix neoplasms; diagnosis design /evaluation; early diagnosis; fiber optics; fluorescence spectrometry; neoplasm /cancer diagnosis; noninvasive diagnosis; reflection spectrometry

DESCRIPTION (Verbatim from the Applicant's Abstract): Cervical cancer is the second most common cause of cancer in women worldwide and the leading cause of cancer related mortality in women in developing countries. We have developed real time non-invasive point-of-care devices to detect early cancerous conditions of cervix. Our preliminary analyses on data collected from a total of 133 patients and have shown promising results. We are continuing to collect data and will include the entire data set into the analysis as part of our phase I objective. Given our limited data set, however, it is not possible to project any definite performance benchmark. We will propose this task to the training and validation phase in a Phase 2 proposal. For the present we want to analyze the data for the purpose of determining the optimum clinical device for the validation phase. To support data accrual in the validation phase we will make multiple clones of this device for deployment in a multicenter clinical trial. The objective of the data analysis is to arrive at this validation device by simplifying and consolidating the complexity and the many features built into each prototype. This will also reduce the possibility of overtraining by reducing the number of parameters we build into our algorithm. PROPOSED COMMERCIAL APPLICATION: The product of this research will be a prototype device capable to spectroscopically detecting and/or diagnosing cervical cancer. Our device has, upon commercialization, the potential to replace or aid the current Pap test as well as to replace the current methods of colposcopy, biopsy and histology. The target physician group for the cervical application is the Ob-Gyn segment. It is estimated that there are at least 30,000 physicians in this segment and upwards of $6 billion spent each year in the US on cervical disease.

描述（逐字摘自申请人摘要）：宫颈癌是 全球女性第二大常见癌症原因，也是导致癌症的主要原因 发展中国家妇女癌症相关死亡率。我们开发了 用于检测早期癌症的实时非侵入性护理点设备 子宫颈的状况。我们对收集到的数据进行初步分析 对 133 名患者进行了研究，并取得了可喜的结果。我们正在持续征集 数据并将整个数据集纳入分析中，作为我们的一部分 第一阶段目标。然而，鉴于我们有限的数据集，不可能 制定任何明确的绩效基准。我们将向 第二阶段提案中的培训和验证阶段。目前我们想要 分析数据以确定最佳的临床设备 验证阶段。为了支持验证阶段的数据累积，我们将 对该设备进行多个克隆，以便在多中心临床中部署 审判。数据分析的目的是实现此验证 通过简化和整合复杂性和众多功能来设计设备 内置于每个原型中。这也将减少以下可能性 通过减少我们构建到算法中的参数数量来避免过度训练。 拟议的商业应用： 这项研究的产品将是一个能够进行光谱检测的原型设备 和/或诊断宫颈癌。 我们的设备在商业化后有潜力 取代或辅助当前的巴氏试验以及取代当前的阴道镜检查方法， 活检和组织学。 宫颈应用的目标医师群体是妇产科医生 部分。 据估计，该领域至少有 30,000 名医生及以上 美国每年在宫颈疾病上花费 60 亿美元。